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Clarithromycin and its metabolite, 14-hydroxy-clarithromycin are active against a
wide range of respiratory pathogens. Antibiotics generally penetrate poorly into
respiratory secretions which may therefore continue to harbour bacteria following
bronchial infection. We have studied sputum and serum concentrations of clarithro-
mycin and 14-hydroxy-clarithromycin in eight patients with idiopathic bronchiecta-
sis without infective exacerbations (five male, three female; mean age 53-3 years).
Oral single dose administration of 250 or 500 mg clarithromycin, separated by at
least 6 days, was given to each patient. Serum and sputum samples were collected
(the latter by physiotherapy at 0, 1, 2, 4, 8, 24 and 0, 4, 8 and 24 h respectively after
administration of each dose. Serum sol phase was obtained by high speed centrifuga-
tion and concentrations of clarithromycin and 14-hydroxy-clarithromycin were
determined by high performance liquid chromatography. Serum Cmml for clarithro-
mycin and 14-hydroxy-clarithromycin were 1-20 mg/L (3 h) and 0-37 mg/L (31 h)
for clarithromycin (250 mg)) and were 2-78 mg/L (2-5 h) and 068 mg/L (2-6 h) for
clarithromycin (500 mg) respectively. Sputum Cnax for clarithromycin and 14-
hydroxy-clarithromycin were 0-52 mg/L (5 h) and 0-30 mg/L (6-5 h) for clarithro-
mycin (250 mg) and were 1-59 mg/L (5 h) and 0-47 mg/L (5-5 h) for clarithromycin
(500 mg) respectively. The sputum/serum percentage ratios at C^ , (sputum) for
clarithromycin and 14-hydroxy-clarithromycin were 74-3% and 113-9% (250 mg)
and 94-7% and 99-9% (500 mg) respectively. We conclude that oral administration
of clarithromycin to patients with bronchiectasis results in rapid penetration into
respiratory mucus with persistent drug concentrations that exceed its MIC for many
respiratory pathogens.
Introduction
Clarithromycin is a new macrolide antibiotic which is a 6-methoxy derivative of
erythromycin. Clarithromycin is more resistant to gastric acid and has a better
pharmacokinetic profile than erythromycin. A metabolite of clarithromycin, 14-
hydroxy-clarithromycin, also has antibiotic activity against Haemophilus influenzae.
Clarithromycin and 14-hydroxy-clarithromycin have an additive effect which reduces
the MIC for this bacterium (Hardy et ai, 1990). Clarythromycin has been shown to be
effective in patients with infective exacerbations of chronic obstructive lung disease
(Guay & Craft, 1992).
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Recent studies (Farley et al., 1986; Baltimore, Christie & Walker-Smith, 1989; Read
et al., 1991) have suggested that bacteria infecting the bronchial tree are largely
associated with intraluminal secretions, rather than adherent to epithelial surfaces.
Therefore a high concentration of antibiotic in sputum is desirable. However the
penetration of many antibiotic classes into secretions is poor (Bergogne-Berezin, 1988;
Valcke, Pauwels & Van der Straeten, 1990). Although the penetration of clarithromycin
into lung tissue has been measured, its penetration into secretions has not. We have
therefore performed an open study of serum and sputum concentrations of clarithro-
mycin and 14-hydroxy-clarithromycin following single oral administration of 250 and
500 mg of clarithromycin in patients with idiopathic bronchiectasis.
Materials and methods
Patient recruitment and specimen collection
Patients with bronchiectasis confirmed by high resolution thin-cut computerized tomo-
graphy were enrolled at a time when their symptoms were stable, there having been no
infective exacerbation within the last 30 days. Patients who regularly produced mucoid
sputum were selected. Nine patients were enrolled during the study period. One patient
was withdrawn from analysis because insufficient sputum was obtained. Analysis was
performed on eight patients (five male and three female; mean age 53-3 years, S.D. 1304,
range 37-71) who had clinically stable idiopathic bronchiectasis. Mean height was
166-9 cm (S.D. 10-4, range 150-0-182-0) and mean weight was 64-5 kg (S.D. 17-9, range
38-93). All patients had normal liver function tests before entering the trial. No patient
had used any concomitant antibiotic, theophylline, carbamazepine, warfarin, digoxin
or long-acting (depot) antibiotics within 30 days before the study.
The first dose of clarithromycin (250 or 500 mg) was administered orally following
an overnight fast, after physiotherapy to clear residual secretions. Serum and sputum
specimens were collected at 0, 1, 2, 4, 8, 24 and 0, 1, 4, 8 and 24 h after administration
respectively. At least six days were allowed before the patients returned for their second
dose of clarithromycin (250 or 500 mg) when specimens were collected similarly. Fresh
sputum specimens were collected by a physiotherapist who provided assistance with
postural drainage. Immediately after collection, serum was obtained by centrifugation
of blood at 1000 g for 5 min at 4°C. Sputum and serum specimens were stored in sterile
containers at — 70°C. Patients provided written informed consent, and the study was
approved by the Ethics Committee of the Royal Brompton National Heart and Lung
Hospital.
Analysis of specimens
The concentrations of clarithromycin and 14-hydroxy-clarithromycin in serum and
sputum (sol phase) specimens were analysed using high performance liquid chromato-
graphy. The apparatus consisted of a pump LKB 2248 with pulse dampener (Phar-
macia, Freiburg, Germany); autosampler SIL-8A (Shimadzu Europe, Duisburg,
Germany); column heater TCM 100 (30°C, Millpore Waters Chromatography,
Eschborn, Germany); electrochemical detector (Coulochem model 5100A: guard cell
5020 set to 1 V, analytical cell 5010 with electrode 1 set to 0-65 V and electrode 2 (for
quantitation) set to 0-85 V) (ESA Inc., Bedford, MA, USA); and integrator C-R4A
(Shimadzu Europe, Duisburg, Germany). Separation was conducted using a Zorbax
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SB-CN column (i.d. 4-6 x 150 mm). The mobile phase consisted of 450 m L 50 mM
sodium dihydrogen phosphate, 300 mL acetonitrile and 50 mL methanol, adjusted to
pH 7-3 with 10 N sodium hydroxide. Using a flow rate of 1 mL/min, the retention
times of the compounds to be analysed were 7-7 min (14-hydroxy-clarithromycin),
131 min (clarithromycin) and 14-7 min (roxithromycin, internal standard).
Serum
To 500 /iL serum were added: 100 /iL water (standards: 100 /iL water containing 1 /ig
clarithromycin and 0-5 /ig 14-hydroxy-clarithromycin), 100 /iL internal standard solu-
tion (10 /ig/mL roxithromycin in water) and 500 /iL acetonitrile for precipitation of
proteins. Mixing was followed by incubation at 4°C for 20 min and centrifugation. The
supernatant was diluted with 1 m L water and transferred into a disposable column
(ADSORBEX R filled with 100 mg C18 silicagel, Merck Company; Darmstadt ,
Germany) which had been equilibrated with 5 mL of methanol followed by 2 mL of
50 mM sodium phosphate buffer (pH = 6-3). After the supernatant had passed through
the extraction column, it was washed twice with 2-5 mL of 50 mM phosphate buffer
(pH = 6-3). The compounds to be investigated were eluted with 1 m L methanol which
was subsequently diluted with 1 mL water and then 50 /iL was injected into the
analytical column.
Sputum
An aliquot of the sputum was adsorbed on to a dental tampon and then transferred to
a SALIVETTER (Sarstedt Company, Nuembrecht, Germany) and centrifuged (1500 g,
20 min). U p to 500 /iL of the sol phase fluid was treated in the same manner as serum.
The methanol eluate from the extraction column was dried under vacuum in a
EVAPOTEC R Vortex-Evaporator (Haake Buchler Company, Saddle Brook, NJ ,
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Table I. Serum concentrations of clarithromycin and 14-hydroxy-
clarithromycin after a single oral dose of 250 mg and 500 mg clarithromycin
Dose 250 mg CL 500 mg CL
time (h) CL (mg/L) HCL (mg/L) CL (mg/L) HCL (mg/L)
0 0±0 0 ± 0 0±0 0±0
1 0-76±0-64 0-2O±0-18 211 ±1-75 0-55±0-46
2 0-93±O59 031 ±0-16 2-65± 1-43 0-56±0-38
4 0-75±O42 O28±0-10 212± 102 0-57±0-36
8 0-54 ±0-34 023 ±008 1-31 ±0-57 045 ±0-24
24 0-09±O09 O07±006 O28±0-24 014±O10
All data are means of eight patients! standard deviation. CL, Clarithromycin; HCL,
14-hydroxy-clarithromycin.
Calibration and control samples
Internal standardization using roxithromycin and quality control was performed by
assaying spiked samples with each run. The detection limit was 400 pg for clarithro-
mycin and 14-hydroxy-clarithromycin and 600 pg for roxithromycin.
Statistical analysis
A repeated measure analysis of variance was undertaken to determine differences in the
mean concentration between drug doses and whether there was a change in concentra-
tion with time. The CmVL of sputum and serum were compared by Wilcoxon signed rank
test. A P value of less than 005 was taken as significant. All analyses were performed
with the aid of the statistical package BMDP (BMDP, 1990).
Results
Serum concentrations (Table I)
The mean concentrations of clarithromycin and 14-hydroxy-clarithromycin were
significantly higher in the 500 mg group than in the 250 mg group (P < 005). The
concentrations of clarithromycin and 14-hydroxy-clarithromycin increased until CmMX
was reached, thereafter decreasing with time. As there were relatively few time points
for sampling, half-lives calculated are very variable and there is no evidence of any
difference in the half-lives calculated for both doses (Table III). The Cmtx for clarithro-
mycin (250 mg) and 14-hydroxy-clarithromycin were 120±039 mg/L and
0-37 ±0-10 mg/L respectively, which occurred at 3 and 31 h. The C,^, of clarithro-
mycin (500 mg) and 14-hydroxy-clarithromycin were 2-78 ±1-31 mg/L and
0-68 ±0-36 mg/L respectively, which occurred at 2-5 and 2-6 h, and were significantly
higher than those following clarithromycin (250 mg) {P < 0-05).
Sputum concentrations (Table II)
The mean concentrations of clarithromycin (P < 0-01) and 14-hydroxy-clarithromycin
(P < 0-05) were significantly higher in the 500 mg group than in the 250 mg group. The
concentrations of clarithromycin and 14-hydroxy-clarithromycin increased until C ^ ,
thereafter decreasing with time. Sputum half-lives were not calculated in view of the
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Table II. Sputum concentrations of clarithromycin and 14-hydroxy-
clarithromycin in patients following a single oral dose of 250 mg and 500 mg
clarithromycin
Dose 250 mg CL 500 mg CL
time (h) CL (mg/L) HCL (mg/L) CL (mg/L) HCL (mg/L)
0 0±0 0+0 0±0 0±0
4 0-4310-34 0-24 ±0-26 149 ±1-02 043 ±0-25
8 O44±0-23 0-2610-16 0911039 0331013
24 O101O07 0-0510-05 0371029 0171016
All data arc means of eight patients ± standard deviation. CL, Clarithromycin; HCL,
14-hydroxy-clarithromycin.
limited data. The Cmu. of clarithromycin (250 mg) and 14-hydroxy-clarithromycin in
sputum were 0-52 ±0-30 and 0-30 ±0-24 mg/L respectively which occurred at 5 h and
6-5 h (Table III). The CmMJ. of clarithromycin (500 mg) and 14-hydroxy-clarithromycin
were 1-591100 mg/L and 0-47 + 0-23 mg/L respectively which occurred at 5 and 5-5 h.
At C,^, only sputum clarithromycin concentration was significantly higher following
500 mg clarithromycin compared with 250 mg clarithromycin (P < 0-05). The sputum/
serum percentage ratios at C ^ (sputum) for clarithromycin and 14-hydroxy-clarithro-
mycin were 74-3% and 113-9% (250 mg clarithromycin) and 94-7% and 99-9% (500 mg
clarithromycin) respectively.
Discussion
These results confirm previously published reports that orally administered clarithro-
mycin is rapidly absorbed and elimination from serum is slow (Ferrero, 1990; Davey,
1991). Peak serum concentrations were achieved 3 h after oral administration of 250
and 500 mg of clarithromycin, while peak sputum concentrations were achieved after
5 h. In this study, the mean serum concentrations of clarithromycin and 14-hydroxy-
clarithromycin are comparable to results of studies performed on healthy individuals
D
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Table III. Pharmacokinetic data for clarithromycin (CL) and 14-hydroxy-clarithromycin (HCL) following a single oral dose.
Q», (mg/L)
TmW
Tia (h)
serum CL
1-2 ±039
(07-1-89)
3-0 ±2-3
(1-8)
8-0 ±4-9
(3-4-18-2)
250
sputum CL
052 ±03
(023-1-14)
50 ±1-9
(4-8)
—
—
mgCL
serum HCL
O37±O1
(O25-O5)
3-1 ±2-2
(1-8)
101 ±4-5
(3-6-16-4)
sputum HCL
03 ±024
(O15-O86)
6-5 ± 2 1
(4-8)
—
—
serum CL
2-78 ± 1 - 3 1
(1-07 ±5-59)
2-5 ±2-3
(1-8)
6-9 ±3-0
(4-3 ±11-6)
500
sputum CL
1-59+10
(062-3-49)
50 ±1-9
(4-8)
—
—
mgCL
serum HCL
068 ±036
(019-1-44)
2-6 ±2-6
(1-8)
12-4 ±150
(3-6 ±461)
sputum HCL
047 ± 0 2 3
(012-085)
5-5 ± 2 1
(4-8)
—
—
Data are means ±s.D. and range obtained from eight patients.
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cularly with intraluminal secretions in the lower respiratory tract (Farley et al., 1986;
Baltimore et al., 1989; Read et al., 1991). Therefore penetration into these sites may
influence the efficacy of an antibiotic. Many antibiotics, particularly the penicillins,
have poor penetration into bronchial secretions (Bergogne-Berezin, 1988; Valcke et al.,
1990). In the present study, the the penetration of clarithromycin and 14-hydroxy-
clarithromycin into sputum was rapid and the concentrations achieved were higher
than those previously reported for /Mactam antibiotics. Drug elimination of clarithro-
mycin and 14-hydroxy-clarithromycin from sputum was slow and measurable concen-
trations of antibiotics were still present in sputum 24 h after a single oral dose of
clarithromycin. For both doses of clarithromycin administered, the sputum to serum
ratio of clarithromycin ranged from 31-9% to 2578% and 14-hydroxy-clarithromycin
ranged from 40-4% to 277-9%. Clarithromycin has also been shown to have good
penetration into lung tissue (Cmai lung tissue 17-47 mg/kg and CmMX serum 2-82 mg/L)
following multiple doses of 500 mg taken orally (Fraschini et al., 1991). Previous
studies on erythromycin generally used multiple doses of erythromycin and have shown
that the penetration of erythromycin ranges from 10% to 50% for bronchial secretions
and sputum (Marlin et al., 1980; Bergogne-Berezin, 1988; Periti et al., 1989), 83% for
bronchial mucus (Brun et al., 1981), and 110% to 320% for lung parenchyma (Wollmer
et al., 1982). Our results indicate that clarithromycin has a higher penetration into
respiratory mucus than erythromycin. Further studies are needed to determine whether
clarithromycin and 14-hydroxy-clarithromycin accumulate in sputum after multiple
doses.
The mean sputum concentrations of clarithromycin and 14-hydroxy-clarithromycin
were compared with the MICs for common respiratory pathogens (King & Phillips,
1991; Piscitelli, Danziger & Rodvold, 1992). After administration of the two doses of
clarithromycin, sputum concentrations of clarithromycin and 14-hydroxy-clarithro-
mycin exceeded the MICs for Streptococcus pneumoniae (0-12 mg/L for clarithromycin
0-015 mg/L for 14-hydroxy-clarithromycin), Moraxella catarrhalis (012 mg/L,
0-12 mg/L), and Streptococcus pyogenes (006 mg/L, 0-03 mg/L), for more than 24 h,
except following 250 mg doses, when the MIC for Streptococcus pneumoniae (clarithro-
mycin) was exceeded for 21-5 h and Moraxella catarrhalis when the MIC was exceeded
for 21-5 h (clarithromycin) and 16-5 h (14-hydroxy-clarithromycin). MICs for
Haemophilus influenzae vary considerably: 2-16 mg/L in one study, 0-75-4 mg/L in
another (Dabernat et al., 1991; Olsson-Liljequist & Hoffman, 1991). However, the MIC
for H. influenzae was not exceeded in sputum following either single dose of clarithro-
mycin. Multiple doses of clarithromycin are known to increase the serum concentra-
tions of clarithromycin, which may be reflected in sputum concentrations. Although
sputum concentrations of clarithromycin and 14-hydroxy-clarithromycin are below the
MIC for H. influenzae, clarithromycin has been shown to be effective in treatment of
patients with infective exacerbation of chronic bronchitis caused by H. influenzae
(Guay & Craft, 1992). The recent finding that H. influenzae infection caused less tissue
damage in the presence of subinhibitory antibiotic concentrations may be relevant in
these circumstances (Tsang et al., 1993).
Macrolide antibiotics have been used more frequently of late because of recognition
of infections caused by bacteria not sensitive to /Mactams, such as mycoplasma,
legionella and chlamydia. Clarithromycin has good sputum penetration in patients with
clinically stable bronchiectasis. This property, and its superior pharmacokinetic profile,
give it clear advantages over older macrolide antibiotics such as erythromycin.
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